Atrial fibrillation (AF), a common and clinically significant cardiac rhythm disturbance, is associated with gut microbial dysbiosis. However, the precise role of the microbiota and associated metabolism in this condition remain unclear. Through integrated analysis of clinical cohorts and multiple animal models, we identified an intestinal symbiont, Ruminococcus gnavus (R. gnavus), which suppresses the occurrence of AF and atrial fibrosis by producing the leucine-derived branched-chain fatty acid isovaleric acid (IVA). R. gnavus colonization or exogenous IVA supplementation reduced AF susceptibility and improved fibrosis-driven atrial remodeling. Mechanistically, R. gnavus metabolizes dietary leucine into IVA through its unique enzyme 2-oxoisovalerate ferredoxin reductase γ-subunit (vorC). Microbiome-derived IVA activates G protein-coupled receptor 109A (GPR109A) on atrial cardiomyocytes, inhibiting interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3) signaling activation and blocking gasdermin E (GSDME)-mediated pyroptosis through a STAT3-GSDME feedforward circuit. These results reveal that the microbial metabolism of dietary leucine and the production of IVA play pivotal roles in preventing AF onset and progression.
Background:Insulin resistance (IR) is a key metabolic determinant of cardiovascular risk. Ceramides, a class of bioactive lipids, have been linked to IR; however, their clinical associations in patients with established coronary artery disease (CAD) are incompletely characterized. Methods:In a prospective, multicenter observational cohort of adults with established CAD (n=987), we quantified plasma ceramide species (Cer16:0, Cer18:0, Cer24:0, Cer24:1) and surrogate IR indices (triglyceride-glucose index (TyG), metabolic score for insulin resistance (METS-IR), and triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C)). Mixed graphical models (MGM) were used to estimate conditional associations within a multivariable network. Double machine learning (DML) with causal-forest estimators provided covariate-adjusted association estimates and probed robustness values (RV) to unmeasured confounding. Exposures were standardized per standard deviation. We also developed a ceramide-augmented model to classify clinical IR, prespecified as TyG ≥ 9, and quantified discrimination by the area under the receiver operating characteristic curve (ROC-AUC). Results:Ceramides correlated with IR indices. In MGM analyses, Cer24:0 showed a direct conditional association with TyG (partial r=0.23; 95% CI, 0.17-0.29), independent of other variables in the network. In DML analyses, per 1-unit increase in ln (Cer24:0) was associated with higher TyG (estimate, 0.459; 95% CI, 0.252-0.665; P = 0.001); These estimates demonstrated moderate RV to unmeasured confounding, with an RV (theta) of 0.223. A ceramide-augmented model classified clinical IR with an ROC-AUC of 0.770 (95% CI, 0.741-0.799). Conclusions:Across complementary analytic frameworks, Cer24:0 consistently exhibited positive associations with lipid-centric IR metrics among adults with established CAD. Although observational, these findings suggest that circulating ceramide profiling-particularly Cer24:0-may refine metabolic risk stratification beyond conventional indices in cardiology practice.
BACKGROUND:The efficacy of mechanical thrombectomy (MT) for treating large infarcts has been established through multiple recent randomized controlled trials (RCTs). Nevertheless, hemorrhagic transformation (HT) remains one of the significant challenges following thrombectomy in these patients. METHODS:This study presents a post-hoc analysis of the Study of Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core (ANGEL-ASPECT) trial. We included all patients with large infarcts who underwent thrombectomy and had imaging data available for HT assessment. Multivariate regression models were developed to determine the predictive factors for post-thrombectomy parenchymal hemorrhage (PH) and examine the relationship between PH and patient outcomes. RESULTS:This study enrolled 217 patients, of whom 35 (16.1%) experienced PH 24-48 hours after thrombectomy. Multivariate analysis showed that patients with PH had a significantly worse functional outcome compared with patients without PH (modified Rankin Scale (mRS) score 5 vs 3, adjusted common OR (acOR) 0.31, 95% CI 0.16 to 0.61, P<0.01). Alcohol use (acOR 3.22, 95% CI 1.29 to 8.03, P=0.01) and an increased number of thrombectomy attempts (acOR 1.43, 95% CI 1.02 to 2.00, P=0.04) were independently associated with a heightened risk of PH. Conversely, local sedative anesthesia (acOR 0.10, 95% CI 0.01 to 0.84, P=0.03) was linked to a reduced risk of PH. CONCLUSIONS:In patients with large infarcts, PH is associated with a poorer functional prognosis after thrombectomy. Alcohol use and a higher number of thrombectomy attempts were positively associated with the occurrence of PH, whereas local sedative anesthesia was negatively correlated with its occurrence. TRIAL REGISTRATION NUMBER:ClinicalTrials.gov Identifier: NCT04551664.
Thrombosis and bacterial infections pose critical challenges for blood-contacting implants, inducing serious morbidity and mortality. Inspired by the vascular endothelium, we present an eco-friendly and facile strategy to construct a structurally enhanced, integrated offensive-defensive coating with exceptional hemocompatibility, biocompatibility, and antibacterial activity. Hierarchical cobblestone-like micro/nanostructures are fabricated on the pyrolytic carbon via femtosecond laser ablation. Subsequently, copper ions (offensive component) are immobilized onto the structured surface through dopamine-mediated adhesion, enabling the catalytic generation of endogenous nitric oxide to actively interrupt the thrombosis cascade and bactericidal action by disrupting their membranes. Following this, a zwitterionic polymer is grafted onto the surface to form a hydration layer (defensive component), which passively inhibits the adhesion of biofoulants. The pre-engineered hierarchical structures effectively enhance copper ion loading capacity, stabilize the interfacial hydration layer, and simultaneously reduce the availability of anchoring sites for biofoulants. The resulting biomimetic coating exhibits excellent biocompatibility, with an ultralow hemolysis rate (0.1%, below ISO 10993-4 standards) and nearly 100% endothelial cell viability after 48 h of coincubation. It also demonstrates robust defensive performance, markedly reducing the adhesion of platelets (by 99.6%), fibrin (by 69.8%), and bacteria (by 99.1% for S. aureus and 95.5% for E. coli) compared to the pristine surface. Additionally, the coating achieves outstanding offensive functionality, with negligible platelet activation and high bactericidal efficiencies of 92.8% and 77.1% against S. aureus and E. coli, respectively. This endothelium-mimicking, drug-free strategy provides a versatile platform for durable, biocompatible cardiovascular implants, potentially reducing clinical complications and improving patient outcomes.